Fiche société
Dianthus Therapeutics
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ClaseprubartThe purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG). | Myasthénie | Phase 3 | À vérifier | United States | À vérifier |
| ClaseprubartThe purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG). | Myasthénie | Phase 2 | À vérifier | United States, Argentina, Canada, Czechia, Denmark, France, Israel, Italy, Netherlands, North Macedonia, Norway, Poland, Serbia, Sweden | À vérifier |
| ClaseprubartThe purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG). | Myasthénie | Phase 3 | À vérifier | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Claseprubart | Myasthénie | Phase 3 | NCT07647510 | A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) | RECRUITING |
| Claseprubart | Myasthénie | Phase 2 | NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | ACTIVE_NOT_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||